Phantom vision after eye removal: prevalence, features and related risk factors

2021 ◽  
pp. bjophthalmol-2021-319091
Author(s):  
Arnaud Martel ◽  
Stephanie Baillif ◽  
Pierre Thomas ◽  
Fabien Almairac ◽  
Olivier Galatoire ◽  
...  

AimPhantom eye syndrome is a poorly understood and underestimated complication of eye removal (ER). Seeing with the amputated eye, referred to as phantom vision (PV), is undoubtedly the most intriguing and confusing complication experienced by anophthalmic patients. The aim of the study was to assess PV prevalence, clinical features and risk factors after ER.MethodsA multicentric questionnaire-based study was conducted between April 2016 and July 2017. Patients >18 years who underwent ER >3 months ago had a socket examination before inclusion. Data recorded included patients’ demographics, and preoperative, surgical and postoperative features.ResultsOne hundred patients (53 men) with a mean age of 65.1 years (29–92; SD=13.0) were included. ER indications were: uveal melanoma (n=24, 24%), trauma (n=20, 20%), retinal detachment (n=20, 20%), glaucoma (n=14, 14%) and endophthalmitis (n=12, 12%). Thirty (30%) patients experienced PV. Elementary and complex visual hallucinations were experienced by 80% and 20% of patients, respectively. PV usually appeared within the first postoperative month and tended to decrease over time. Risk factors for PV were the preoperative use of proton beam therapy (p=0.006), uveal melanoma (p=0.014), enucleation (p=0.015), anxiety with a Hospital and Anxiety Depression (HAD) score ≥8 (p=0.042), depression with a HAD score ≥8 (p=0.030), phantom eye pain (p=0.044) and phantom eye sensations (p=0.002).ConclusionPV was reported by one-third of our patients. Despite being widely misunderstood, ophthalmologists and neurologists should be aware of this complication to adequately reassure patients.

2016 ◽  
Vol 254 (9) ◽  
pp. 1787-1792 ◽  
Author(s):  
Ira Seibel ◽  
Dino Cordini ◽  
Annette Hager ◽  
Johanna Tillner ◽  
Aline I. Riechardt ◽  
...  

2015 ◽  
Vol 160 (4) ◽  
pp. 628-636 ◽  
Author(s):  
Ira Seibel ◽  
Dino Cordini ◽  
Matus Rehak ◽  
Annette Hager ◽  
Aline I. Riechardt ◽  
...  

Author(s):  
A.L. Polishchuk ◽  
D.H. Char ◽  
V. Weinberg ◽  
I.K. Daftari ◽  
T.B. Cole ◽  
...  

Author(s):  
Zi Di Lim ◽  
Edwin Pheng ◽  
Evelyn Tai Li Min ◽  
Hans Van Rostenberghe ◽  
Ismail Shatriah

Platelets are a primary source of pro- and anti-angiogenic cytokines. However, the evidence of their role in retinopathy of prematurity (ROP) is controversial. This retrospective study aimed to compare mean weekly platelet counts between infants with and without ROP over the first 6 weeks of life. A total of 93 infants matched by gestational age and birth weight were recruited (31 with ROP, 62 without ROP). Weekly mean platelet counts and other related risk factors were documented. The repeated measure analysis of variance (ANOVA) and the repeated measure analysis of covariance (ANCOVA) were used to compare mean platelet counts over time between the two groups, with and without adjusting for confounders. We found significant differences in the weekly mean platelet counts of infants with and without ROP over the first 6 weeks of life (p = 0.002). These differences disappeared after adjusting for covariates (p = 0.489). Lower mean platelet counts in ROP infants are not directly related to ROP, but rather to the presence of other risk factors for ROP, such as culture-proven sepsis, blood transfusion and bronchopulmonary dysplasia.


2011 ◽  
Vol 79 (3) ◽  
pp. 842-846 ◽  
Author(s):  
Laura Marucci ◽  
Marek Ancukiewicz ◽  
Anne Marie Lane ◽  
John M. Collier ◽  
Evangelos S. Gragoudas ◽  
...  

2013 ◽  
Vol 85 (5) ◽  
pp. 1218-1224 ◽  
Author(s):  
Jean-Pierre Caujolle ◽  
Vincent Paoli ◽  
Emmanuel Chamorey ◽  
Celia Maschi ◽  
Stéphanie Baillif ◽  
...  

2016 ◽  
Vol 168 ◽  
pp. 31-39 ◽  
Author(s):  
Ira Seibel ◽  
Annette Hager ◽  
Aline I. Riechardt ◽  
Anja M. Davids ◽  
Alexander Böker ◽  
...  

2017 ◽  
Vol 256 (2) ◽  
pp. 411-420 ◽  
Author(s):  
Amir Mahdjoubi ◽  
Marie Najean ◽  
Stéphanie Lemaitre ◽  
Sylvain Dureau ◽  
Rémi Dendale ◽  
...  

2017 ◽  
Vol 27 (5) ◽  
pp. 596-600 ◽  
Author(s):  
Ariane Malclès ◽  
Anh-Minh Nguyen ◽  
Thibaud Mathis ◽  
Jean-Daniel Grange ◽  
Laurent Kodjikian

Purpose To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT). Methods Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile. Results Mean age was 55.6 years (range 34-85). Mean time between PBT and DEX-I was 12.4 months (range 3-25). Mean follow-up was 9.9 months (range 4-15). Intravitreal Ozurdex® reduced exudative RD in 7 cases (70%) on average 3.1 months after injection with complete resolution of RD in 6 of these (60%). For half of the patients, their level of vision remained stable; the other half experienced a deterioration in visual acuity at the end of follow-up. No adverse effects were observed. Conclusions In this small case series, treatment with intravitreal DEX-I reduced exudative RD in the majority of cases and had an acceptable safety profile.


Sign in / Sign up

Export Citation Format

Share Document